H1B Salary Data

Home › Employers › HealthLogix LLC

HealthLogix LLC: H-1B salaries and sponsorship

HealthLogix LLC filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $105,000.

Applications (LCAs)3
Certified3
Employer addressParsippany, NJ
H-1B dependent employerNo
Median offered salary$105,000
Middle half of salaries$105,000–$109,000
10th–90th percentile$105,000–$111,400

Does HealthLogix LLC sponsor H-1B visas?

HealthLogix LLC filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on May 27, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Senior Associate Director, Medical and Scientific Affairs3$105,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20263$105,000

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Senior Associate Director, Medical and Scientific Affairs$105,000
Level II
New York, NYMay 27, 2026Oct 1, 2026Certified
Senior Associate Director, Medical and Scientific Affairs$113,000
Level II
New York, NYMay 11, 2026Oct 1, 2026Certified, then withdrawn
Senior Associate Director, Medical and Scientific Affairs$105,000
Level II
New York, NYApr 22, 2026Oct 1, 2026Certified, then withdrawn

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).